Overview

Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD

Status:
Terminated
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
This initial proof of concept, phase II study aims to assess the safety and efficacy of UK-500,001 for the chronic maintenance treatment of adults with Chronic Obstructive Pulmonary Disease.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer